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Abstract
BACKGROUND—Cancers arise from multiple acquired mutations, which presumably occur 
over many years. Early stages in cancer development might be present years before cancers 
become clinically apparent.
METHODS—We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells 
from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic 
mutations on the basis of unusual allelic fractions. We used data from Swedish national patient 
registers to follow health outcomes for 2 to 7 years after DNA sampling.
RESULTS—Clonal hematopoiesis with somatic mutations was observed in 10% of persons older 
than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal 
expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and 
TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a 
strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 
5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had 
clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. 
Analysis of bone marrow–biopsy specimens obtained from two patients at the time of diagnosis of 
acute myeloid leukemia revealed that their cancers arose from the earlier clones.
CONCLUSIONS—Clonal hematopoiesis with somatic mutations is readily detected by means of 
DNA sequencing, is increasingly common as people age, and is associated with increased risks of 
hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid 
cancers is frequently mutated in apparently healthy persons; these mutations may represent 
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characteristic early events in the development of hematologic cancers. (Funded by the National 
Human Genome Research Institute and others.)
THE DEVELOPMENT OF DISEASE OFTEN involves dynamic processes that begin years or decades before the 
clinical onset. In many cases, however, the process of pathogenesis goes undetected until 
after the patient has symptoms and presents with clinically apparent disease.
Cancer arises owing to the combined effects of multiple somatic mutations, which are likely 
to be acquired at different times.1 Early mutations may be present many years before disease 
develops. In some models of cancer development, early mutations lead to clonal expansions 
by stem cells or other progenitor cells.2 Such clonal expansions greatly increase the 
likelihood that later, cooperating mutations would arise in cells that already contain the 
earlier, initiating mutations. To understand the pathogenesis of proliferative diseases, it is 
important to know the extent to which clonal expansions occur and precede cancer.
Hematopoietic stem-cell population dynamics may precede many hematologic cancers, 
including myeloproliferative neoplasms,3 myelodysplastic syndromes,4 acute myeloid 
leukemia (AML),5,6 and chronic lymphocytic leukemia.7 For example, in some patients, 
stem cells carrying a subset of the mutations present in the cancer cells are able to survive 
chemotherapy; subsequently, these cells acquire novel mutations, triggering a relapse.8-10 
This suggests that a clonally expanded stem-cell population may have existed before the 
cancer developed.
Clonal mosaicism for large chromosomal abnormalities, reflecting expansion of a specific 
cellular clone, appears to arise in approximately 2% of elderly persons and is a risk factor 
for later hematopoietic cancers.11-15 In principle, clonal expansion among hematopoietic 
stem cells — a phenomenon termed “clonal hematopoiesis” — could be much more 
common16 and only occasionally accompanied by chromosomal abnormalities.
Many studies today sequence blood-derived DNA from thousands of persons to identify 
inherited risk factors for common diseases. We reasoned that such data offered the 
opportunity to test the hypothesis that clonal expansions with somatic mutations are 
common and often precede blood cancers and to identify the genes in which mutations drive 
clonal expansions.
METHODS
STUDY PARTICIPANTS AND WHOLE-EXOME SEQUENCING OF BLOOD-DERIVED DNA
We obtained blood samples for DNA sequencing from 12,380 Swedish persons (mean age at 
time of sample collection, 55 years [range, 19 to 93]) (see Fig. S1 in the Supplementary 
Appendix, available with the full text of this article at NEJM.org). This cohort included 
6245 controls, 4970 persons with schizophrenia,17,18 and 1165 persons with bipolar disorder 
(Table S1 in the Supplementary Appendix). We treated case patients and controls as a single 
cohort for all analyses presented below, because none of the mutational variables analyzed 
showed any significant relationship to psychiatric diagnosis after we controlled for other 
factors such as age and smoking status. DNA was extracted directly from peripheral venous 
blood samples. All procedures were approved by the relevant ethics committees, and written 
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informed consent was obtained from all participants. Methods of DNA sequencing and 
analysis are described in detail in the Supplementary Appendix.
IDENTIFICATION OF SOMATIC MUTATIONS
We developed a strategy for identifying somatic mutations on the basis of allelic fractions. 
Assuming that a somatic mutation would be present in only a subset of the cells from which 
we obtained DNA for analysis, we predicted that the mutant allele would be present in less 
than 50% of the sequencing reads arising from that genomic site (Fig. 1A and 1B). We 
describe this analytic approach in detail in the Supplementary Appendix.
ANALYSES OF SUBSEQUENT MEDICAL OUTCOMES AND CANCERS
Medical histories (from 1965 to 2012) for 11,164 participants were extracted from the 
Swedish national inpatient, outpatient, and cause-of-death registers. We used these data to 
follow health outcomes for 2 to 7 years after DNA sampling. For 2 participants who 
received a diagnosis of cancer 2 and 34 months after the initial DNA sampling, bone 
marrow–biopsy specimens (obtained at the time of diagnosis) were analyzed by means of 
whole-exome and whole-genome sequencing.
RESULTS
CHARACTERISTIC MUTATIONS AND CANDIDATE DRIVERS IN CLONAL HEMATOPOIESIS
We analyzed whole-exome sequencing data from 12,380 persons and identified 3111 
putative somatic mutations on the basis of their presence at unusual allelic fractions, for a 
frequency of approximately 1 putative somatic mutation for every 4 participants. For all 65 
mutations tested, molecular validation confirmed that the mutant allele was present at a low 
allelic fraction (<50%) and thus could not have been inherited (Fig. S7 in the Supplementary 
Appendix).
The vast majority of the mutations were dispersed across the genome. However, four genes 
(DNMT3A, TET2, ASXL1, and PPM1D) had disproportionately high numbers of somatic 
mutations. Although more than 94% of the mutations observed across the genome were 
missense and synonymous changes, the somatic mutations observed in DNMT3A, TET2, 
ASXL1, and PPM1D had a strong tendency to disrupt gene protein-coding sequences by 
introducing a frame-shift, nonsense, or splice-site disruption (Fig. 2A). Three of these four 
genes — DNMT3A, TET2, and ASXL1 — also tend to harbor such mutations in hematologic 
cancers19-21 and are proposed to function as epigenetic regulators.22
Mutations in PPM1D, which functions as a regulator of tumor-suppressor protein p53,23 
have been described more frequently in nonhematologic cancers. Of the 15 protein-
truncating mutations observed in PPM1D, 12 occurred in the last exon, which is also the site 
of protein-truncating mutations described in patients with cancer.24-27 Loss of the C-
terminal localization domain of PPM1D is reported to activate PPM1D, repress p53, and 
thereby impair the p53-dependent G1 checkpoint, promoting proliferation.26
Somatic mutations in DNMT3A were also characterized by a significant excess of missense 
mutations (P<0.001) (Fig. 2A), all localized in exons 7 to 23, and were enriched for 
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cysteine-forming mutations (Fig. S9 in the Supplementary Appendix). Such mutations 
potentially exert a dominant-negative effect on the tetrameric DNMT3A protein complex 
(see the Supplementary Appendix for details).
Because DNMT3A, TET2, and ASXL1 are frequently mutated in hematologic cancers,28,29 
we hypothesized that other recurring cancer mutations might also promote clonal 
hematopoiesis. We therefore considered 208 specific variants reported as recurring (found in 
≥7 patients) in hematopoietic and lymphoid cancers, as listed in the Catalogue of Somatic 
Mutations in Cancer30 (see the Supplementary Appendix for details). We found 98 instances 
of these recurring mutations, including JAK2 mutation p.V617F31 in 24 participants, 
DNMT3A mutation p.R882H32 in 15 participants, and SF3B1 mutation p.K700E33 in 9 
participants.
Disruptive mutations in DNMT3A, TET2, ASXL1, and PPM1D, missense mutations in 
DNMT3A, and the recurring cancer-associated mutations comprised a set of 327 candidate 
driver somatic mutations for clonal hematopoiesis in 308 participants (Fig. 2B, and Table S3 
in the Supplementary Appendix), with 18 participants carrying multiple candidate drivers 
(Fig. 2C). DNMT3A had the most observed mutations (190), followed by ASXL1 (35) and 
TET2 (31). Mutations in TET2 and ASXL1 were probably undercounted for technical reasons 
(Fig. S6B and S6C in the Supplementary Appendix).
CLONAL HEMATOPOIESIS WITH UNKNOWN DRIVERS
Somatic mutations may be either drivers, which contribute to clonal expansion, or 
passengers, which do not; either could indicate the presence of a clone. Participants having 
clonal hematopoiesis with candidate drivers tended to carry more additional putative somatic 
mutations than participants without candidate drivers (mean number of additional mutations, 
1.5 vs. 0.2; P<0.001 after correction for age) (Fig. S11A in the Supplementary Appendix).
A total of 459 participants had multiple putative somatic mutations without any of the 
candidate drivers described above. Estimates of allelic fraction were more similar in pairs of 
somatic mutations observed in the same person than in pairs of somatic mutations observed 
in different persons (P<0.001 by the Mann–Whitney test), a finding consistent with the 
possibility that the mutations were present in the same clone.
To consider cases of clonal hematopoiesis without obvious driver mutations, we sought to 
define a highly specific criterion for clonal hematopoiesis that depended on the number of 
mutations alone, rather than on the identity of the mutations. Of 11,845 participants with 
sequencing data of sufficient quality for the detection of somatic mutations, 9927 had no 
putative somatic mutations, 1333 had 1 mutation, 313 had 2 mutations, and 272 had 3 to 18 
mutations. This distribution suggested that a random (Poisson) process (with a constant 
mean) could not explain the surprisingly high numbers of participants with 3 to 18 
detectable mutations. In our analyses below, we classified 195 participants as having clonal 
hematopoiesis with unknown drivers. In some cases of clonal hematopoiesis with unknown 
drivers, additional analysis suggested potential candidate drivers (Fig. S12 in the 
Supplementary Appendix).
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CLONAL HEMATOPOIESIS AND ADVANCING AGE
Detectable clonal hematopoiesis with candidate drivers was rare among younger participants 
(occurring in 0.7% of participants younger than 50 years of age) but much more common 
among older participants (occurring in 5.7% of participants older than 65 years of age) (Fig. 
2D). Reflecting this relationship, participants having clonal hematopoiesis with candidate 
drivers were, on average, older than those without detectable putative somatic mutations 
(mean age, 64 years vs. 55 years; P<0.001); each of the most common driver genes 
(DNMT3A, ASXL1, TET2, PPMD1, and JAK2) also tended to have detectable somatic 
mutations in older persons (Fig. S11B in the Supplementary Appendix).
Given that 459 participants had multiple somatic mutations without clear candidate driver 
mutations, we sought to understand the extent to which clonal hematopoiesis with unknown 
drivers arises dynamically over the life span (as opposed to being a lifelong property — e.g., 
due to somatic mutations that occurred in embryonic development34). The observation of a 
single somatic mutation in the exome was common at all ages, in contrast to the strongly 
age-dependent acquisition of clonal hematopoiesis with candidate drivers (Fig. S13 in the 
Supplementary Appendix). However, the presence of two detectable putative somatic 
mutations was more age-dependent, occurring in 1.3% of persons younger than 50 years of 
age as compared with 4.0% of those older than 65 years of age (Fig. S13 in the 
Supplementary Appendix). The presence of three or more putative somatic mutations (our 
criterion for clonal hematopoiesis with unknown drivers) was more strongly age-dependent, 
occurring in only 0.3% of persons younger than 50 years of age but in 4.6% of those older 
than 65 years of age (Fig. 2D). This age trajectory is similar to that of clonal hematopoiesis 
with candidate drivers.
Overall, clonal hematopoiesis with candidate or unknown drivers was observed in 0.9% of 
participants younger than 50 years of age but in 10.4% of those older than 65 years of age 
(Fig. 2D). For participants with clonal hematopoiesis, the average number of detected 
putative somatic mutations also increased with age (P<0.001 by linear regression) (Fig. S14 
in the Supplementary Appendix).
CLONAL HEMATOPOIESIS AND SUBSEQUENT HEMATOLOGIC CANCER AND DEATH
Participants with clonal hematopoiesis were substantially more likely to receive a first 
diagnosis of hematologic cancer 6 months or more after DNA sampling (Table S6 in the 
Supplementary Appendix) than participants without any detectable putative somatic 
mutations (hazard ratio, 12.9; 95% confidence interval [CI], 5.8 to 28.7; P<0.001 by Cox 
proportional-hazards analysis of time to a diagnosis of hematologic cancer, with adjustment 
for age and sex) (Fig. 3A). Participants with candidate drivers and those with unknown 
drivers had similarly elevated risks (Fig. 3B). Of the 31 participants who received a 
diagnosis of hematologic cancer more than 6 months after DNA sampling, 13 participants 
(42%) had shown clonal hematopoiesis in their initial DNA sample (Fig. 3C). Participants 
with clonal hematopoiesis were also more likely than those without clonal hematopoiesis to 
have a history of hematologic cancer, though this did not contribute to the above result 
(Table S7 in the Supplementary Appendix).
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Participants with clonal hematopoiesis had reduced overall survival (hazard ratio for death, 
1.4; 95% CI, 1.0 to 1.8; P = 0.03 by Cox proportional-hazards model, with adjustment for 
age and sex) (Fig. 3D and 3E). A total of 54 participants with clonal hematopoiesis died 
during follow-up (Table S8 in the Supplementary Appendix). In our cohort, the reduced 
overall survival was explained by deaths from cancer and by an association of clonal 
hematopoiesis with smoking (odds ratio, 2.2; 95% CI, 1.4 to 3.4; P<0.001) (see the 
Supplementary Appendix for details).
MALIGNANT CLONES IN DNA SAMPLES
Two participants with clonal hematopoiesis received a diagnosis of myeloid cancer just 2 
months after DNA sampling. We hypothesized that the clone inferred from whole-exome 
sequencing analysis might have been the malignant clone at a preclinical stage (see the 
Supplementary Appendix for details).
Whole-genome sequencing analysis of the preclinical blood DNA sample revealed 1153 
putative somatic mutations at a characteristic frequency in Participant 1 and 660 such 
mutations in Participant 2 (Fig. 4A and 4B), evidence that a clone had amplified from a 
single cell and that was consistent with the number of mutations observed in AML 
genomes.29 The whole-genome sequencing data showed that many known pathogenic 
mutations were present at the characteristic allele frequency of the clone (Fig. 4A and 4B). 
At 2 months before receiving a diagnosis of the myelodysplastic syndrome, Participant 1 
carried mutations in RUNX1, STAG2, SRSF2, and TET2 at the allelic fractions characteristic 
of the clone and also carried an ASXL1 mutation at a slightly higher allelic fraction 
(potentially consistent with a founder mutation). Mutations in ASXL1, RUNX1, and STAG2 
tend to co-occur in myelodysplastic syndromes.35 At 2 months before receiving a diagnosis 
of AML, Participant 2 carried 2 mutations in CEBPA: an in-frame C-terminal 33-bp 
insertion and a frame-shift N-terminal deletion. These 2 types of CEBPA mutation 
frequently co-occur in AML.36
GENETIC RELATIONSHIP OF LEUKEMIA TO EARLIER CLONES
We analyzed bone marrow–biopsy specimens obtained at the time of diagnosis from two 
participants: Participant 2, who carried the two CEBPA mutations, and Participant 3, who 
received a diagnosis of AML 34 months after DNA sampling (see the Supplementary 
Appendix for details).
Analysis of the specimen obtained from Participant 2 confirmed the presence of the 
mutations detected in the earlier DNA sample, including the two CEBPA mutations and 
three passenger mutations now observed at higher allelic fractions (20.5% vs. 15.5% 2 
months earlier; estimate based on the three single-nucleotide substitutions). Cancers 
characterized by pairs of CEBPA mutations tend to have a favorable prognosis,37 and indeed 
this patient had a complete remission after chemotherapy and did not have a relapse.
The hematologic cancer in Participant 3 appeared to be a subclone of the clone detected 
initially, which had undergone additional clonal evolution in the intervening 34 months. A 
TP53 p.R248Q mutation, present at an allelic fraction of 24% in the initial sample, had 
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expanded to 86%, which was consistent with the loss of the other copy of chromosome 17 
and with the 86% blast count in the bone marrow–biopsy specimen. DNA analysis of the 
biopsy specimen indicated losses of chromosome 17 and 5q (results that were consistent 
with the karyotype findings) and a complex pattern of gains and losses on chromosomes 12, 
13, 16, and 19 (Fig. S15 in the Supplementary Appendix). Losses of 17 and 5q are common 
in persons with TP53 mutations.38 By using these segmental losses to distinguish between 
alleles on the lost segments and alleles on the retained segments, we estimated that there 
were already losses of 5q and 17 at low allelic fractions (8% and 3% of cells, respectively) 
in the initial DNA sample but with no losses on chromosomes 12, 13, 16, and 19 or with 
losses at an undetectable frequency at that time (Fig. S16 in the Supplementary Appendix). 
Because the biopsy specimen showed all these events at high allelic fractions, we concluded 
that these mutations arose in a series of subclones (Fig. 4C). The patient died 2 months after 
diagnosis.
DISCUSSION
We observed clonal hematopoiesis with somatic mutations in 10% of the elderly study 
participants, with increasing frequency with age (Fig. 2D). Most such clonal expansions 
appeared to involve driver genes and mutations that are also driver mutations in hematologic 
cancers (Fig. 2A and 2B). We found the presence of such clones to be a risk factor for 
subsequent hematologic cancers (hazard ratio, 12.9; 95% CI, 5.8 to 28.7) (Fig. 3A and 3B) 
and death (hazard ratio, 1.4; 95% CI, 1.0 to 1.8) (Fig. 3D and 3E).
Most cases of clonal hematopoiesis appeared to involve mutations in a specific subset of the 
genes recognized as drivers of blood cancers,22 such as DNMT3A, ASXL1, and TET2 (Fig. 
2A). Other common mutational drivers of such cancers — for example, activating mutations 
in FLT3 and NPM129 — were not observed in these subclinical clonal expansions. Such data 
suggest that mutations in DNMT3A, ASXL1, and TET2 are often initiating mutations that 
remain in subclinical states for long periods; FLT3 and NPM1 mutations may tend to be 
later, cooperating events. Such an inference would align with data from studies involving 
patients with cancer and mouse models.12-14 Functional experiments have shown that loss of 
DNMT3A impairs differentiation of hematopoietic stem cells, resulting in an increase in the 
number of such cells in the bone marrow,39 and that loss of TET2 results in increased self-
renewal of hematopoietic stem cells and a competitive growth advantage.40
We detected clonal hematopoiesis in 42% of the participants who received a diagnosis of 
cancer more than 6 months later (Fig. 3C), and such clones were a strong risk factor for 
these cancers. Our results raise the question of whether DNA sequencing of blood samples 
on a regular basis could enable early detection of blood cancers. On the basis of the current 
data, we believe that such an approach would be premature. Clonal hematopoiesis with 
somatic mutations was detected in 10% of elderly participants, and the absolute risk of 
conversion from clonal hematopoiesis to hematologic cancer was modest (1.0% per year). 
Moreover, there are no currently available interventions that seem suitable for large cohorts 
of patients with only a modest likelihood of cancer. Caution is also warranted when cancer-
associated mutations are observed as an incidental finding in other studies or diagnostic 
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tests: our results suggest that such findings may be common and do not justify a diagnosis of 
hematologic cancer, though they do signify an elevated risk.
In the future, however, it may be possible to refine our DNA analysis in order to develop 
strategies for early detection and even prevention of hematologic cancer. DNA analysis will 
offer three important capabilities: the ability to ascertain high-risk states, the ability to 
monitor the progression or remission of these states, and the ability to ascertain follow-on, 
transforming mutations before clinically apparent illness. Several important research 
directions could bring DNA sequencing for clonal hematopoiesis closer to clinical 
usefulness. First, some somatic mutations are likely to be associated with a particularly high 
risk of subsequent cancer; larger studies could identify such mutations. Second, single-cell 
analyses might identify high-risk combinations of mutations occurring in the same cells. 
Third, the sequencing of specific cell types might identify mutation–cell-type combinations 
with increased predictive value. Fourth, initial detection of clonal hematopoiesis might 
justify periodic screening for the presence of cooperating mutations at low allele frequencies 
that could presage cancer (Fig. 4C). Larger studies will be needed to gather the necessary 
data to evaluate these possibilities.
In addition, the use of DNA sequencing to identify at-risk cohorts and monitor clonal 
expansions, as reported here, could facilitate clinical trials of strategies to reduce the risk of 
progression to cancer. In other areas of medicine, such as cardiovascular disease, biomarkers 
(e.g., low-density lipoprotein cholesterol) that identify high-risk groups of patients and are 
used to obtain rapid information on the efficacy of interventions have been critical in 
developing preventive therapies. It will also be important to understand the extent to which 
clonal hematopoiesis is a marker for the declining health of hematopoietic stem-cell 
populations, potentially reflecting aging, attrition, and a declining ability to contain new 
neoplasms.
These findings illustrate a way in which DNA sequencing offers information about dynamic 
processes that progress over the course of a person’s life and are predictive of clinical 
disease and death. We speculate that an improved ability to predict future harm in 
asymptomatic persons may eventually replace the traditional dichotomy between illness and 
health with a continuum of ascertainable genomic states that are associated with elevated 
risks of future illness.
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Figure 1. Clonal Expansion and Allelic Fractions
Panel A shows a model for the expansion of a single hematopoietic stem cell into a clonal 
population, under the influence of a somatic mutation (yellow circle), and the potential 
conversion of the clone into a hematologic cancer through subsequent mutation (black circle 
with red rim). Mutations present in the founder cell would be present at an appreciable 
allelic fraction (though <50%) in blood-derived genomic DNA. Panel B shows the 
distribution of allelic fractions observed in sequencing data for high-confidence, ultra-rare 
variants ascertained in the 12,380 study participants; the small bump at the left of this 
distribution represents putative somatic mutations.
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Figure 2. Candidate Driver Somatic Mutations
Panel A shows all genes identified as carrying a significant excess of disruptive (nonsense, 
frame-shift, and splice-site) somatic mutations among 11,845 participants with sequencing 
data of sufficient quality for the detection of somatic mutations. To control for potential 
systematic sequencing artifacts due to sequence context, somatic mutations observed in 
multiple participants were counted only once. Panel B shows the contribution of individual 
genes to the total number of candidate driver somatic mutations that were observed. Panel C 
shows a comutation plot for participants with multiple candidate driver somatic mutations. 
Panel D shows estimates for participants with clonal hematopoiesis with candidate drivers 
(carrying at least one candidate driver mutation), those with clonal hematopoiesis with 
unknown drivers (carrying three or more detectable somatic mutations and no candidate 
drivers), and those with clonal hematopoiesis and candidate or unknown drivers. The shaded 
bands represent 95% confidence intervals.
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Figure 3. Risk of Hematologic Cancer for Participants with Clonal Hematopoiesis
Panels A and D show Kaplan–Meier plots of the proportions of participants who did not 
receive a diagnosis of hematologic cancer (Panel A) and for surviving participants (Panel 
D). Panels B and E show hazard ratios for hematologic cancer (Panel B) and death (Panel E) 
for participants with exactly one putative somatic mutation and no candidate drivers (one 
mutation), those with exactly two putative somatic mutations and no candidate drivers (two 
mutations), those with clonal hematopoiesis and unknown drivers (CH-UD), those with 
clonal hematopoiesis and candidate drivers (CH-CD), and those having clonal hematopoiesis 
with candidate or unknown drivers (CH), all compared with participants with no candidate 
drivers and no putative somatic mutations (no mutations). Panel C shows the proportions of 
participants who had clonal hematopoiesis with candidate or unknown drivers among 31 
participants in whom hematologic cancers were diagnosed at least 6 months after DNA 
sampling, as compared with the proportions in a group of age-matched persons without 
hematologic cancer over a similar follow-up period.
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Figure 4. Hematopoietic Clones and Evolution in Three Patients Who Subsequently Received a 
Diagnosis of Myeloid Cancer
Panels A and B show the allelic fraction and coverage for rare heterozygous variants 
ascertained through whole-genome sequencing in Participant 1 and Participant 2, 
respectively, each of whom received a diagnosis of myeloid cancer 2 months after DNA 
sampling. Blue shading indicates the strength of evidence that a mutation was somatically 
acquired, with the negative log10 P value for the mutation being at an allelic fraction of less 
than 50% according to a binomial test. Mutations in black were initially ascertained through 
whole-exome sequencing. Mutations in red are candidate driver mutations. The histograms 
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show the overall distribution of allelic fractions, with the candidate driver mutations 
indicated in red. Panel C shows the progression from clonal hematopoiesis to myeloid 
cancer in Participant 3, in whom DNA was sampled 34 months before diagnosis and again at 
the time of diagnosis. Shading represents cell populations defined by specific combinations 
of mutations as shown; the percentages refer to the estimated representation of each cell 
population in the sample, at initial DNA sampling and then at the time of diagnosis (34 
months later).
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